# A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

> **NCT07221188** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 1250 (estimated)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Efimosfermin Alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221188
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2028-03-24
- **Final completion:** 2028-03-24
- **Target enrollment:** 1250 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221188, "A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07221188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*